PI SZ phenotype in chronic obstructive pulmonary disease

L Alvarez-Granda, M J Cabero-Perez, A Bustamante-Ruiz, D Gonzalez-Lamuño, M Delgado-Rodriguez, M Garcia-Fuentes

Abstract

Background – A study was undertaken to clarify whether the PI SZ phenotype of the protease inhibitor system predisposes to chronic obstructive pulmonary disease (COPD).

Methods – The prevalence of PI Z and PI SZ deficient phenotypes was investigated in a population of 702 patients with COPD followed up at the Chest Unit of a tertiary hospital and in 15 400 newborn infants from the same geographical area. Individuals with deficiency were detected by screening of dried blood spots on filter paper using a comparative electroimmunodiffusion technique for α_1 -antitrypsin and transferrin. The serum phenotype was confirmed by means of isoelectrofocusing on polyacrylamide gel.

Results – Of the 702 blood samples from patients with COPD, six PI Z subjects (0.85%) and one PI SZ (0.14%) were detected. Of the 15 400 samples from neonates, the number of PI Z subjects was eight (0.052%) and that of PI SZ was 24 (0.156%). The difference between the two groups was significant for PI Z but not for PI SZ.

Conclusions – The data do not indicate an increased risk for development of COPD associated with the PI SZ phenotype but confirm the predisposition of PI Z individuals for the development of COPD.

(Thorax 1997;52:659-661)

Keywords: α_1 -antitrypsin, chronic obstructive pulmonary disease, neonates, screening.

others⁶⁷ fail to support this conclusion. The prevalence of this phenotype in a population of patients with COPD compared with that found in newborn infants from the same geographical area was investigated with the aim of clarifying whether the PI SZ phenotype predisposes to the development of chronic respiratory disease.

Methods

STUDY POPULATION

A patient was considered as eligible if he or she had a diagnosis of COPD (chronic bronchitis and emphysema) and was receiving medical care at the Chest Unit of Valdecilla Hospital in Cantabria (Spain) in 1993. Inclusion criteria were diagnosis of symptomatic COPD, forced expiratory volume in one second (FEV₁) less than 80% predicted, and a ratio of FEV₁ to forced vital capacity (FVC) of less than 70%. All the 702 patients eligible gave their consent to participate.

Between 1987 and 1989 15 400 neonates in our region were also studied to determine the prevalence of α_1 -antitrypsin deficiency.

SCREENING METHOD

The technique used for screening was a modification of that described by Laurell⁸ and consisted of a simultaneous electroimmunodiffusion assay for α_1 -antitrypsin and transferrin in the following stages: (1) elution of 40 mm² of filter paper impregnated with capillary blood in 75 μ l saline serum (0.9%) for 24 hours; (2) the eluate (5 μ l per sample) is subjected to electrophoresis on agar gel containing anti- α_1 -antitrypsin (5.8%) and anti-transferrin (5%) antibodies (Behring), with the application of a continuous voltage of 10 volts/cm for four hours. The plates were then stained with Coomassie Blue.

The result of the electrophoresis corresponded to two peaks delimited by the antigen-antibody precipitation lines. The concentration of antisera in the gel was such that, in samples from normal non- α_1 -antitrypsin deficient individuals, the two peaks attain similar heights. The samples from patients with severe α_1 -antitrypsin deficiency produced a transferrin peak of normal height and a very low α_1 -antitrypsin peak. To avoid failure to detect PI SZ individuals, samples suspected of being deficient were considered to be those in which the ratio of the heights of the α_1 -antitrypsin/transferrin peaks was less than or equal to 0.65. This cut-off point was chosen after the finding

Department of Paediatrics

L Alvarez-Granda
M J Cabero-Perez
D Gonzalez-Lamuño
M Garcia-Fuentes

Chest Unit

A Bustamante-Ruiz

University Hospital of Valdecilla, Santander, Spain

Division of Preventive Medicine and Public Health, University of Cantabria School of Medicine, Av. Cardenal Herrera Oria s/n 39011, Santander, Spain
M Delgado-Rodriguez

Correspondence to:
Dr M Garcia-Fuentes.

Received 26 June 1996

Returned to authors

1 October 1996

Revised version received

21 February 1997

Accepted for publication

24 March 1997

Table 1 Clinical and radiological features and pulmonary function of patients with PI Z phenotype

Patient no.	Age	Sex	Smoking (pack/years)	Dyspnoea grade	Age CB	Radiographic findings		Bullae on CT scan	Hypoxaemia	FEV ₁ (% predicted)	TLCO
						Hyperinflation	Bullae				
1	35	M	40	3	24	+++	+	+	Yes	29	↓
2	34	M	30	2	29	+	—	+	No	63	↓
3	40	M	40	3	32	+++	+	+	Yes	25	↓
4	62	F	0	3	37	+	—	+	No	73	↓
5	40	M	8	3	36	+	—	+	Yes	38	↓
6	66	F	5	3	51	+	—	+	Yes	45	↓

Age CB = age at which criteria of chronic bronchitis fulfilled; TLCO = carbon monoxide transfer factor.

in a pilot study of 102 newborn infants and 50 patients with COPD that no PI SZ individual was identified above this point.

In those individuals with suspect samples on immunodiffusion, a blood sample was taken and the serum phenotype was determined by isoelectrofocusing at pH 4.2–4.9 on polyacrylamide gel⁹ and the α_1 -antitrypsin serum level was determined by immunonephelometry (Beckman).

CLINICAL STUDY

Case histories were taken from all PI Z and PI SZ individuals who underwent physical examination and analysis of basic haematological and biochemical parameters including hepatic enzymes. PI Z and PI SZ individuals from the population with COPD also underwent chest radiography, computed axial tomographic (CT) scanning, spirometric and pulmonary function tests.

DATA ANALYSIS

The comparison of prevalences was carried out using the Fisher exact test.

Results

There was a predominance of men (79.8%), of smokers (80.5%), and of those aged 40–60 years (57.4%) in the study population. Mean (SD) FEV₁ was 1.14 (0.32) l (56 (17)% predicted). FEV₁/FVC was 54 (14)%.

Of the 702 patients with COPD subjected to screening, 17 (2.4%) were found to have an α_1 -antitrypsin/transferrin ratio of less than 0.65. Phenotype determination showed that six of these were PI Z and one was PI SZ; the rest consisted of five PI MZ, three PI MS, and two PI MM. In the neonate population 58 (3.8/1000) suspect samples were detected of which eight were PI Z and 24 PI SZ; the remaining suspect samples consisted of one PI FS, three PI SS, five PI MZ, five PI MS, six PI MM, and six infants whose phenotype we were unable to determine. The number of PI Z individuals found in the group of patients with COPD was significantly higher ($p < 0.001$) than that found in the neonates. The difference was not significant for PI SZ ($p = 0.975$).

The six COPD patients with PI Z presented with emphysema (table 1). Four subjects were aged ≤ 40 . All presented with radiological and CT findings compatible with emphysema. The PI SZ individual detected was a 60 year old man with clinical and spirometric criteria of

COPD five years previously. After his inclusion in the study population he was diagnosed as having extrinsic allergic alveolitis after exposure to avian antigens.

With respect to the neonate population, four of the eight PI Z individuals detected presented with hepatomegaly; one child developed cirrhosis and portal hypertension, while the other three presented at one year with persistent hepatomegaly and raised hepatocellular enzymes. The remaining four PI Z individuals were asymptomatic with no biochemical changes. The 24 PI SZ neonates were also asymptomatic, and only one presented with slightly raised hepatocellular enzymes.

Discussion

Although the association between the Pi Z phenotype and the development of pulmonary emphysema is well known, it is at present impossible to predict the natural history of a PI Z individual. The number of PI Z individuals with emphysema is well below the total number of these individuals in the population¹⁰ and, in most screening studies carried out on the general population, the PI Z individuals detected present with low levels of respiratory disease.¹¹ This lack of knowledge is more marked when we consider PI SZ individuals. It is unclear whether this phenotype involves a risk of developing pulmonary emphysema. Further understanding on this matter is important as the number of PI SZ individuals in the population is 2–3 times greater than that of the PI Z phenotype.

In the controversy about the pulmonary involvement of this phenotype, an initial study described the association of PI SZ with pulmonary emphysema⁴ which resulted in PI SZ being considered a risk phenotype. However, the number of PI SZ individuals recorded with emphysema is clearly lower than the number of PI Z individuals despite being a more frequent phenotype, and this suggests that the SZ phenotype does not involve any special risk for the development of respiratory disease.⁶

The number of studies on the prevalence of PI Z and PI SZ individuals in COPD populations is small. Only two studies have analysed populations of over 500. Lieberman⁷ found a prevalence of PI Z of 1.9% in 965 patients with COPD and reported no difference between these patients and normal individuals with regard to the number with the PI SZ phenotype. On the other hand, Bartman⁵ found five PI Z and 18 PI SZ individuals in 526 patients with COPD compared with two PI Z and one PI

SZ individuals in the control population. In our study we have found only one PI SZ individual among the patients with COPD, the same frequency as in our control group. However, because of the low prevalence of PI SZ in the population, larger studies may be necessary to exclude a small increase in COPD with PI SZ phenotype.

It was unknown before the beginning of our study whether PI SZ caused ill health so we chose neonates as a control population. In control groups of healthy adults the prevalence of PI Z and PI SZ may be underestimated because these individuals may develop initial symptoms in the second decade of life and are thus not adequately represented in control populations of adult groups.

Our study shows no involvement of the SZ phenotype in the risk for COPD. The frequency of COPD in PI Z individuals was far higher than that found in the neonate population ($p < 0.001$), thus confirming the results of other studies with small populations of patients with COPD.

- 1 Hutchison DCS. Epidemiology of α_1 -protease inhibitor deficiency. *Eur Respir J* 1990;3(Suppl 9):29-34.
- 2 Gadek JE, Crystal RG. Alpha-1-antitrypsin deficiency. In: Stanbury JB, Wyngaarden JB, Fredrickson DS, Goldstein JL, Brown MS, eds. *The metabolic basis of inherited diseases*. New York: McGraw-Hill, 1982:1450-65.
- 3 Larsson C. Natural history and life expectancy in severe alpha₁-antitrypsin deficiency, Pi Z. *Acta Med Scand* 1978; 204:345-51.
- 4 Larsson C, Dirksen H, Sundstrom G, Eriksson S. Lung function studies in asymptomatic individuals with moderately (Pi SZ) and severely (Pi Z) reduced levels of alpha-1-antitrypsin. *Scand J Respir Dis* 1976;57:267-80.
- 5 Bartmann K, Fooke-Achterrath M, Koch G, Nagy I, Schültz I, Weis E, et al. Heterozygosity in the Pi system as a pathogenetic cofactor in chronic obstructive pulmonary disease (COPD). *Eur J Respir Dis* 1985;66:284-96.
- 6 Hutchison DCS, Tobin MJ, Cook PJJ. Alpha-1-antitrypsin deficiency: clinical and physiological features in heterozygotes of Pi type SZ. A survey by the British Thoracic Association. *Br J Dis Chest* 1983;77:28-34.
- 7 Lieberman J, Winter B, Sastre A. Alpha antitrypsin Pi-types in 965 COPD patients. *Chest* 1986;89:370-3.
- 8 Laurell C-B. A screening test for α_1 -antitrypsin deficiency. *Scand J Clin Lab Invest* 1972;29:247-8.
- 9 Jeppsson J-O, Franzen B. Typing of genetic variants of α_1 -antitrypsin by electrofocusing. *Clin Chem* 1982;28:219-25.
- 10 Tobin MJ, Cook PJJ, Hutchison DCS. Alpha-1-antitrypsin deficiency: the clinical and physiological features of pulmonary emphysema in subjects homozygous for Pi type Z. *Br J Dis Chest* 1983;77:14-27.
- 11 Morse JO, Lebowitz MD, Knudson RJ, Burrows B. Relation of protease inhibitor phenotypes to obstructive lung diseases in a community. *N Engl J Med* 1977;296:1190-4.